Skip to content

Impact of a Nurse for Migraine Management: the IMPACT Project

Impact of a Nursing Intervention on the Clinical Evolution of Patients at a University Migraine Clinic

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01804517
Acronym
IMPACT
Enrollment
200
Registered
2013-03-05
Start date
2013-02-28
Completion date
2015-11-30
Last updated
2016-12-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Migraine, Migraine With Aura, Migraine Without Aura

Keywords

migraine

Brief summary

Headache disorders are prevalent, disabling, under recognized, under diagnosed and under treated. Migraine has a prevalence of 10% in men and 25% in women in Canada. The treatment of migraine is based on patient education (lifestyle habit modification, trigger avoidance), and pharmacological acute treatment and prophylaxis. A multidisciplinary approach allows a repartition of tasks between different health professionals. In a 2010 meeting, the Canadian Headache Society members supported the concept of Headache Centers, and a headache nurse was judged as an essential component of such centers. Gaul has reviewed the structured multidisciplinary approach that could be used in a headache centre and the existing studies using such structures. Five studies did include a headache nurse. No study did observe the impact of a nurse only. Resources in medical care are limited. One study did use a program of 96 hours, which does not seem realistic on the long-term and for a large pool of patients in a public hospital. Patients are not always able to pay for paramedical help such as physiotherapy and psychotherapy. Even if they do, finding a specialized therapist for chronic headache is difficult. Defining the role of a nurse and demonstrating the impact on patient care is therefore a first step in the concept of a headache center. Possible roles of a headache nurse according to Gaul are patient education, follow-up of the treatment plan, addressing patient queries, and monitoring of patient progress. The headache nurse may also participate in research projects. In a hospital Headache Clinic, the nurse may be involved in intra-venous treatments and blood sampling for research. In summary, evidence to demonstrate the impact of a nurse in a headache clinic is lacking. We propose to study this aspect prospectively. A study with positive findings would encourage health ministers to fund and support headache nurses for headache centers across Canada for headache management. Chronic headache and therefore chronic migraine would be a focus of such centers, since most patients seen in specialized centers are chronic. HYPOTHESIS: The addition of a headache nurse to the headache team will help the CHUM Migraine Clinic to improve treatment outcome, and reduce the burden of headache. This multidisciplinary approach will also allow a higher efficiency of the team.

Detailed description

STUDY DESIGN: The goal of this study is to compare two treatment approaches for migraineurs. The first approach will be based on the physician only and is limited to fixed appointments (control group). The second approach will be based on a team involving a headache nurse (active group) who will participate in patient education and follow-up. The goal is to improve patient outcome but also physician productivity. First 100 patients (control group, phase 1): patients with episodic and chronic migraine will be screened, sign consent and be enrolled. They will be seen by the physician only, without the nurse's support. This situation will reproduce the actual conditions at the clinic. During this phase, the nurse will be involved in the follow-up of known patients (who will not be included in the protocol) and data collection. She will develop her headache management abilities and help the physicians to develop some educational tools for patients. Following 100 patients (active group, phase 2) : patients with episodic and chronic migraine will be screened and enroled. They will be seen by the physician and nurse team, with a treatment plan tailored to specific needs including regular scheduled visits, follow-up of chronification factors and educational sessions. Phone call follow-ups will be planned. Patients will have an easier and quicker contact with the team in an emergency situation.

Interventions

None listed

Sponsors

Allergan
CollaboratorINDUSTRY
Notre-Dame Hospital, Montreal, Quebec, Canada
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age 18 or more * Diagnosis of migraine, chronic or episodic, at the first visit. We expect the majority of patients to suffer form frequent or chronic migraine. * Consent to participate in the CHUM Migraine Clinic IMPACT project. * For future post-hoc analysis, groups will be stratified according to baseline headache frequency (all severity included), assessed retrospectively at the first visit: * \<6 headache days per month, * 6 to 14 headache days per month * 15 or more headache days per month

Exclusion criteria

* Patients whom first headache diagnosis is not migraine (for example post-traumatic headache, cluster headache, trigeminal neuralgia, facial pain). * Women with ongoing or planned pregnancy. * Patient with an active psychiatric condition (needing hospitalisation or psychosis). * Patient with mental retardation impairing assessment or follow-up. * Patient with an active medical condition which may lead to frequent hospitalisations (eg active cancer, organ graft, hemodialysis etc). This will be determined and detailed by the evaluating physician. * Active drug addiction or alcoholism. * Active follow-up at a pain clinic. * Patient speaking a language other than french and incapable to communicate in a reliable way.

Design outcomes

Primary

MeasureTime frameDescription
Hit-6 score changeBaseline and 8 monthsHIT-6 score change between inclusion and 8 month.

Secondary

MeasureTime frameDescription
Frequency of headache daysBaseline and 8 monthsChange in the frequency of headache days, all severity included, between the first month and the seventh and eight months following inclusion.
Chronic headache statusBaseline and 1 yearPercent of patients who were chronic (more than 3 months with \>15 headache days per month, retrospective) at entry and were episodic at one year (according to calendars).
Medication overuseBaseline and 8 monthsPercent of patients with medication overuse at entry and were not overusing anymore at 8 months.
Acute medication intakeBaseline and 8 monthsChange in the number of days per month with acute medication use between the first month after inclusion and the seventh and eight months following inclusion.
Efficacy of acute treatmentat 8 monthsPercent of patients who succeeded in finding a successful and properly used acute treatment at month eight, according to four criteria: efficacy, reliability, absence of recurrence, absence of significant side effects.
Response rate to prophylacticsat 8 monthsPercent of patients who did complete a successful (\>50% response and no significant side-effects) preventive treatment trial at month eight after inclusion.
Frequency of moderate and severe headache daysBaseline and 8 monthsVariation in the frequency of moderate or severe headache days per month between the first, fourth and eighth month after inclusion.
Visits to the emergency departmentover 1 yearNumber of headache-related emergency department visits per patient during the year following their inclusion.
Severe adverse effects from treatmentsover 1 yearPercent of patients with a severe adverse effect from a treatment (necessitating hospitalization, emergency visit or specific treatment).
Phone calls returnedper 1 monthNumber of phone calls returned per month
Patient satisfactionat 8 monthsSatisfaction of patients, evaluated by a customized questionnaire.
Phone call return delayfor each phone call, meanMean delay for returning the call (number of week days between the date of the call and the date of the return).
Global improvementat 8 monthsEvaluation of physician of the global improvement of the patient.
Short Form 12 scoreBaseline and 8 monthsChange in SF-12 scores between inclusion and third visit. SF-12 is a quality of life questionnaire.

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026